Related Experiment Video

Updated: Nov 5, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

340

Heart failure risk estimation based on novel biomarkers

Feven Ataklte1, Ramachandran S Vasan2,3,4,5

  • 1Department of Internal Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA, USA.

Expert Review of Molecular Diagnostics
|May 20, 2021
PubMed

Insights

Biomarkers aid in predicting and managing heart failure (HF). Novel multi-omic approaches show promise for personalized HF treatment and improved patient outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Biomarker Research
  • Genomics and Proteomics

Background:

  • Heart failure (HF) continues to have high morbidity and mortality despite medical advances.
  • There is a critical need for improved methods in HF prediction, screening, and prognosis for effective prevention.
  • Understanding HF's complex etiologies is key to developing better management strategies.

Purpose of the Study:

  • To review current and emerging biomarkers for heart failure (HF).
  • To discuss the role of biomarkers in HF screening, diagnosis, prognosis, and prediction.
  • To explore the potential of multi-omic approaches in HF management.

Main Methods:

  • Systematic literature review of PubMed and Google Scholar up to December 2020.
  • Key search terms included: biomarker, novel, heart failure, risk, prediction, estimation.
  • Analysis of established, emerging, and promising biomarkers for HF.

Main Results:

  • BNP and troponin are established biomarkers for HF diagnosis and prognosis.
  • Emerging biomarkers like galectin-3 and ST-2 are recognized for HF prognosis.
  • Cardiorenal biomarkers show promise but are not yet standard clinical recommendations.

Conclusions:

  • Multi-marker and multi-omic approaches are increasingly utilized due to the complex nature of HF.
  • These advanced assays offer potential for novel therapeutic discoveries.
  • Precision medicine in HF can be significantly improved through these newer methodologies.

Keywords:
Biomarkerheart failuremulti-markeromicspredictionprognosisscreening

More Related Videos

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction14:19

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction

Published on: October 14, 2016

11.7K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.7K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
287
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
473
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
139
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
102
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.1K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
63